Ironwood Pharmaceuticals, Inc. — Q2 2015 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2015; unaudited. Ironwood is a commercial-stage pharmaceutical company whose principal marketed product is linaclotide, sold in the U.S. as LINZESS with Allergan and in certain foreign markets as CONSTELLA or LINZESS through partners.
Financial performance and position
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Collaborative arrangements revenue | $27.7 million | $6.8 million | $56.7 million | $21.4 million |
| Operating loss | $42.0 million | $55.1 million | $70.1 million | $99.5 million |
| Net loss | $48.0 million | $60.4 million | $81.2 million | $110.0 million |
| Basic and diluted loss per share | $0.34 | $0.44 | $0.57 | $0.82 |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $(61.3) million | $(94.1) million |
Q2 and first-half revenue increased 306% and 164%, respectively. The primary driver was Ironwood’s U.S. LINZESS profit share: $16.0 million in Q2 and $33.4 million in the first half, compared with losses shared in the prior-year periods. Revenue is reported as collaborative arrangements revenue; the filing does not provide a conventional product-sales gross margin.
Research and development expense was $28.6 million in Q2 and $55.3 million in the first half, up 29% and 12%. Selling, general and administrative expense was $33.0 million and $63.3 million, up 12% and 7%. Cost of revenue was $8.2 million in the first half, down from $12.4 million. The company remained loss-making and reported an accumulated deficit of $1.05 billion.
At June 30, 2015, cash and cash equivalents were $256.5 million and available-for-sale securities were $236.9 million, for $493.3 million in unrestricted cash, cash equivalents and securities. Total current assets were $527.0 million and current liabilities were $62.1 million. Cash and cash equivalents rose from $74.3 million at year-end, principally following the convertible-note financing. First-half investing cash use was $65.9 million, largely reflecting net purchases of short-term securities; financing cash provided was $309.4 million.
Ironwood issued $335.7 million principal amount of 2.25% convertible senior notes due 2022, receiving approximately $324.0 million net proceeds. The notes’ June 30 carrying amount was $214.3 million after accounting for the conversion feature and debt discount; principal was $335.7 million. The company also had 11% PhaRMA notes, with $165.4 million carrying amount and approximately $17.6 million of principal expected to be paid within the following 12 months. Management cited total indebtedness of approximately $504.8 million.
Material changes versus the prior comparable period
- Revenue growth chiefly reflected stronger U.S. LINZESS profit sharing, alongside approximately $1.0 million of Cologuard co-promotion revenue in the first half and increased AstraZeneca-related revenue.
- Net losses narrowed, mainly as revenue rose; research and development and commercial spending increased as Ironwood continued product development and LINZESS support.
- Partner demand and regulatory timing changes prompted a $5.0 million linaclotide API inventory write-down and a $3.2 million accrual for excess non-cancelable purchase commitments. Inventory was zero at June 30, compared with $5.0 million at year-end.
- The June 2022 convertible-note issuance materially increased liquidity and debt. Convertible note hedges and related warrants were recorded as Level 3 derivatives; changes in fair value affect earnings.
Outlook, commentary, and risks
- Management expects continued losses and substantial research, development and commercialization expenses for the foreseeable future. It stated that available cash at June 30 should fund projected operating needs for at least 12 months, while cautioning that estimates could prove wrong. No numerical revenue or earnings guidance is provided.
- In July 2015, Ironwood and AstraZeneca reported positive top-line Phase III linaclotide results in China. China’s revised regulatory review process had lengthened the expected timeline.
- Commercial and supply risks include dependence on Allergan and other partners, reimbursement and pricing uncertainty, competition, and reliance on third-party manufacturers. Almirall had suspended German commercialization of CONSTELLA over reimbursement pricing.
- Debt-service capacity depends partly on LINZESS performance and payments from Allergan. The PhaRMA notes carry an 11% rate and are linked to U.S. LINZESS sales; the 2022 notes create conversion, potential dilution and cash-repurchase exposure under specified circumstances.
- After quarter-end, Ironwood agreed to co-promote Allergan’s VIBERZI in the U.S. It also amended two API supply agreements; disclosed commercial supply obligations total $34.5 million through 2023.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the period.
Important facts for investors to verify
- Whether U.S. LINZESS demand and profit sharing sustain the revenue improvement, and how partner-reported sales and costs affect Ironwood’s share.
- Whether reduced European and delayed Chinese partner demand leads to further inventory charges or changes in the remaining API purchase commitments.
- Cash burn against management’s stated 12-month liquidity outlook, including ongoing pipeline and commercialization spending.
- Debt terms and servicing: the PhaRMA notes’ sales-linked payments, the convertible notes’ conversion and repurchase provisions, and the potential effects of the hedge and warrant transactions.
- Progress on reimbursement in Germany and other markets, China regulatory review, and linaclotide clinical and post-marketing programs.